Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept

Abstract

Tumour necrosis factor (TNF)-α antagonists are used for treatment of psoriasis and are generally effective and well tolerated (1,2). However, a substantial proportion of patients lose effect over time. The underlying mechanisms are unclear, but data suggest that formation of anti-drug antibodies leads to sub-therapeutic drug levels and thereby loss of efficacy (3).

This article is protected by copyright. All rights reserved.

http://ift.tt/2rQf21h